Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

ash, cash equivalents and marketable securities will be at least $125 million at the end of 2013, inclusive of research funding from Shire but exclusive of funds arising from any additional new collaborations or partnerships, or other new sources. 

The Company reiterates its earlier guidance as follows:

  • Revenues: Sangamo expects that revenues will be in the range of $20 to $24 million in 2013, inclusive of research funding from Shire.
  • Operating Expenses: Sangamo expects that operating expenses will be in the range of $46 to $50 million for 2013.
  • Conference CallSangamo will host a conference call today, Wednesday, October 23, 2013, at 5:00 p.m. ET, which will be open to the public.  The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm.  A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to the rest of 2013. 

    The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 79054132.  For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 23, 2013 to 11:59 p.m. ET on October 30, 2013. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 79054132. 

    About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Co
    '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
    2. Sangamo BioSciences Proposes Public Offering Of Common Stock
    3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
    4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
    5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
    6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
    7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
    8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
    9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
    10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
    11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/30/2015)... , March 30, 2015 /CNW/ - A new national ... the salaries and demographic profiles of new graduates entering ... Door – Building Careers for New Grads in Biotech," ... Research-Based Pharmaceutical Companies (Rx&D) and features data collected ... Focus wage subsidy program from 2013 to 2015. ...
    (Date:3/30/2015)... , March 30, 2015  Naldemedine, an ... development by Shionogi & Co., Ltd., met its ... study (COMPOSE I) for the treatment of opioid-induced ... pain receiving opioid therapy. Study results showed that ... significantly improved the frequency of spontaneous bowel movement ...
    (Date:3/29/2015)... , March 29, 2015 ... of important study data showing the presence ... 1,599 gynecologic cancer samples. Using Caris Molecular ... service, researchers identified expression of programmed cell ... independent of histology while its ligand (PD-L1) ...
    (Date:3/27/2015)... , March 27, 2015  Neogen Corporation (NASDAQ: ... adopted a prearranged trading plan in accordance with Securities ... Chairman and CEO of Neogen Corporation, is a minority ... Corporation common stock. Herbert does not have ... appropriate. The filing is only for a portion of ...
    Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2
    ... the only Apo-Al/HDL drug to be highlighted, ... /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix" or the "Company") (TSX:RVX) ... featured prominently in an article titled,"Emerging Antidyslipidemic Drugs", ... of Emerging Drugs, a well respected scientific journal ...
    ... Position in the U.S. and ... in Key Global Markets, ... Closing, JERUSALEM and MONTVALE, N.J., July 18 Teva,Pharmaceutical Industries ... ) announced today that they have signed a definitive,agreement under which ...
    ... available in French . , ... , , A novel super-resolution X-ray microscope developed by a team ... in Switzerland combines the high penetration power of x-rays with ... to shed light on the detailed interior composition of semiconductor ...
    Cached Biology Technology:Resverlogix's Lead Drug Featured in Key Scientific Publication 2Teva to Acquire Barr 2Teva to Acquire Barr 3Teva to Acquire Barr 4Teva to Acquire Barr 5Teva to Acquire Barr 6Teva to Acquire Barr 7Teva to Acquire Barr 8Super-resolution X-ray microscopy 2
    (Date:3/12/2015)... FAIRFAX, Va. , March 12, 2015 ... company and a member of the Texas Instruments Design ... Chandrababu Naidu has demonstrated its IriShield USB MK2120U ... iris scanning facility for pension distribution. ... and assembled to be marketed in India ...
    (Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
    (Date:3/10/2015)... , March 10, 2015   Tute Genomics , ... been selected by next-generation sequencing company PrimBio Research ... exome and targeted gene panel interpretation. PrimBio, ... adopted the most current technologies to support the work ... The company offers two types of exome sequencing services: ...
    Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
    ... future may be closer than you would think. A recent ... 2009 issue of the American Journal of Botany ... used to predict the future dynamics of plant communities, an ... as global climate change and invasive species, are affecting current ...
    ... Iowa Srinivas Aluru recently stepped between the two rows ... and showed off the 3,200 computer processor cores that power ... lot of raw power in those racks. Cystorm, a ... calculations per second. That,s five times the peak of CyBlue, ...
    ... Japanese research group led by Professor Junichi Nabekura ... that, after cerebral stroke in one side of the ... neural circuits to recuperate from damaged neural function. The ... They report their finding in Journal of Neuroscience ...
    Cached Biology News:Seeing the tree from the forest: Predicting the future of plant communities 2New Iowa State supercomputer, Cystorm, unleashes 28.16 trillion calculations per second 2New Iowa State supercomputer, Cystorm, unleashes 28.16 trillion calculations per second 3
    Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
    Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
    Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
    Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
    Biology Products: